Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 43Carcinoma, Neuroendocrine 8Gastro-enteropancreatic neuroendocrine tumor 7Sarcoma 6Carcinoid Tumor 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Paraganglioma 5Neoplasms 5Prostatic Neoplasms 4Pheochromocytoma 4Neoplasm Metastasis 4Lung Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma 4Thyroid Neoplasms 3Neuroblastoma 3Carcinoma, Renal Cell 3Thyroid Diseases 2Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Neuroectodermal Tumors 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Site 2Neoplasms by Histologic Type 2Meningioma 2Medulloblastoma 2

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Metatropic dwarfism × NET × Clear all
NCT03629847 2018-08-14

Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue

King Faisal Specialist Hospital & Research Center

Phase 1/2 Unknown
30 enrolled
EndocrineNET

Metatropic dwarfism, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡